Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap Up – Should You Buy?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s share price gapped up prior to trading on Monday . The stock had previously closed at $4.20, but opened at $4.58. Perspective Therapeutics shares last traded at $4.53, with a volume of 275,388 shares changing hands.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CATX. B. Riley Financial increased their price target on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Royal Bank Of Canada lowered their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. Finally, Truist Financial set a $12.00 price objective on Perspective Therapeutics in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Stock Performance

The business has a 50-day moving average price of $4.78 and a 200-day moving average price of $3.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. The firm had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. Sell-side analysts expect that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Perspective Therapeutics by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after acquiring an additional 163,532 shares during the last quarter. Avidity Partners Management LP increased its stake in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock worth $8,830,000 after acquiring an additional 216,700 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after acquiring an additional 188,887 shares during the last quarter. Opaleye Management Inc. acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $3,257,000. Finally, State Street Corp increased its position in shares of Perspective Therapeutics by 3.3% during the 4th quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after purchasing an additional 36,543 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.